Boundless Bio Entered into a Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate Lytgobi + BBI-355 for FGFR Amplified Solid Tumors
- The companies collaborated to evaluate Taiho’s Lytgobi (pan-FGFR inhibitor) + BBI-355 in P-I/II trial (POTENTIATE) for patients with LA or metastatic solid tumors with oncogene amplifications whose disease has progressed despite all standard therapies
- Taiho will be responsible for providing futibatinib clinical drug supply at no cost for ongoing P-I/II trials (POTENTIATE). The combination therapy offers the potential to demonstrate anti-tumor activity for patients with cancer and FGFR amplification
- BBI-355, an orally administered, novel, selective checkpoint kinase 1 (CHK1) inhibitor & is the 1st ecDTx being investigated for oncogene amplified cancer
Ref: Businesswire | Image: Taiho
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.